8-K: Fortress Biotech Faces Milestone Uncertainty as AstraZeneca's Anselamimab Fails Primary Endpoint in Phase III AL Amyloidosis Trial

Fortress Biotech's potential to receive up to $125 million in milestones is jeopardized after AstraZeneca announced its AL amyloidosis drug, anselamimab, failed to meet its primary endpoint in a Phase III clinical trial.

Summary

• AstraZeneca's Cardiac Amyloid Reaching for Extended Survival (CARES) Phase III clinical program for anselamimab (formerly CAEL-101), a proprietary product candidate for the treatment of light chain (AL) amyloidosis, did not achieve statistical significance for its primary endpoint.
• The primary endpoint was defined as a hierarchical combination of time to all-cause mortality (ACM) and frequency of cardiovascular hospitalizations (CVH) in patients with Mayo stages IIIa and IIIb AL amyloidosis.
• Fortress Biotech, Inc. (Fortress) founded Caelum Biosciences, Inc. (Caelum), which developed CAEL-101 and was acquired by AstraZeneca's Alexion Therapeutics, Inc. on October 6, 2021.
• Fortress previously received approximately $57 million upfront under the Caelum Acquisition.
• Fortress remains eligible to additionally receive up to approximately $125 million of the up to $295 million that is remunerable to all former stockholders of Caelum, upon the satisfaction of certain regulatory and sales milestones.
• AstraZeneca stated that anselamimab showed highly clinically meaningful improvement in time to ACM and frequency of CVH in a prespecified subgroup of patients, compared to placebo.
• Anselamimab was reported to be well tolerated, with the majority of events balanced between the anselamimab treatment arm and the placebo arm.
• AstraZeneca indicated that evaluation of full results from the CARES program is ongoing, and the company plans to share these data with global health authorities and present them at a forthcoming medical meeting.

Sentiment

Score: 3

Explanation: The primary endpoint failure of a key partnered drug candidate significantly reduces the likelihood of Fortress Biotech receiving substantial milestone payments, which is a material negative financial impact. While there's a subgroup finding, it doesn't fully offset the primary failure.

Positives

• Anselamimab showed highly clinically meaningful improvement in time to all-cause mortality and frequency of cardiovascular hospitalizations in a prespecified subgroup of patients compared to placebo.
• Anselamimab was well tolerated, with the majority of events balanced between the treatment and placebo arms.

Negatives

• Anselamimab did not achieve statistical significance for the primary endpoint in the CARES Phase III clinical program for Mayo stages IIIa and IIIb AL amyloidosis.
• The failure of the primary endpoint jeopardizes Fortress Biotech's eligibility to receive up to $125 million in potential future milestone payments from the Caelum Acquisition.

Risks

• Difficulty predicting the timing or outcome of regulatory interactions, approvals, or actions, including those pertaining to the prespecified subgroup of patients identified by AstraZeneca in its CARES clinical program.
• Risks relating to Fortress Biotech's growth strategy, financing, and strategic agreements and relationships.
• Need for substantial additional funds and uncertainties relating to financings.
• Ability to identify, acquire, close, and integrate product candidates successfully and on a timely basis.
• Ability to attract, integrate, and retain key personnel.
• The early stage of products under development.
• Uncertainties relating to preclinical and clinical testing.
• Ability to obtain regulatory approval for products under development.
• Ability to successfully commercialize products for which regulatory approval is received or receive royalties or other distributions from third parties.
• Ability to secure and maintain third-party manufacturing, marketing, and distribution of products and product candidates.
• Government regulation, patent and intellectual property matters, and competition.

Future Outlook

AstraZeneca is continuing the evaluation of full results from the CARES program to further characterize the efficacy and safety of anselamimab. The company plans to share these data with global health authorities and present them at a forthcoming medical meeting. Fortress Biotech's ability to receive future milestone payments is contingent on these future developments and regulatory outcomes.

Industry Context

The failure of a Phase III clinical trial for a drug targeting a rare disease like AL amyloidosis highlights the inherent risks in pharmaceutical development, even for promising candidates. While the subgroup analysis offers a glimmer of hope, the primary endpoint miss is a significant setback for the program and for companies like Fortress Biotech that rely on milestone payments from such partnerships. This outcome underscores the high bar for regulatory approval and the challenges of demonstrating broad efficacy in complex patient populations.

Stakeholder Impact

• Shareholders: Potential negative impact due to reduced likelihood of future milestone payments, which could affect the company's valuation and stock price.
• Customers/Patients: Patients with AL amyloidosis may face continued unmet needs or delays in accessing new treatments if anselamimab's path to market is hindered.

Next Steps

• AstraZeneca is evaluating full results from the CARES program to further characterize efficacy and safety.
• AstraZeneca plans to share the full data with global health authorities.
• AstraZeneca plans to present the full data at a forthcoming medical meeting.

Key Dates

Recommendation

Keywords

Fortress Biotech, FBIO, AstraZeneca, Alexion, Caelum Biosciences, CAEL-101, anselamimab, AL amyloidosis, Phase III clinical trial, CARES program, milestone payments, biotechnology, pharmaceuticals, clinical trial results, SEC filing, 8-K